Teladoc Health Inc (TDOC) FinancialsTDOCTeladoc Health Inc

Teladoc Health Inc (TDOC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Access Fees Revenue, accounting for 78.1% of total sales, equivalent to $474.21M. Another important revenue stream is Other. Understanding this composition is critical for investors evaluating how TDOC navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Teladoc Health Inc maintains a gross margin of 53.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.82%, while the net margin is -8.42%. These profitability ratios, combined with a Return on Equity (ROE) of -12.99%, provide a clear picture of how effectively TDOC converts its operational activities into shareholder value.

In the context of the broader market, TDOC competes directly with industry leaders such as LMRI and OPK. With a market capitalization of $1.13B, it holds a significant position in the sector. When comparing efficiency, TDOC's gross margin of 53.58% stands against LMRI's 10.90% and OPK's 37.32%. Such benchmarking helps identify whether Teladoc Health Inc is trading at a premium or discount relative to its financial performance.

Teladoc's revenue has shown a decline, with Q2 2026 revenue at $606.9 million, down 4% year-over-year. The company has also reported consistent net losses, with a loss per share of $0.21 in Q2 2026, which is worse than the previous year's loss.